MENOPAUSE: MODERN STANDARDS OF DIAGNOSIS AND CORRECTION OF DISORDERS

DOI: https://doi.org/10.29296/25877305-2021-03-12
Download full text PDF
Issue: 
3
Year: 
2021

N. Volotskaya, A. Sulima, Z. Rumyantseva S.I. Georgievsky Medical academy, V.I. Vernadsky
Crimean Federal University, Simferopol

Objective of the Review: to study and systematize the clinical and experimental research data about menopause and disorders associated with sex hormone deficiency, to assess the safety and efficiency of correction of disorders in menopause, using menopausal hormone therapy (MHT) or alternative methods. Key Points: Menopause is often accompanied by variable symptoms and a decrease in the quality of life. MHT is recognized as the most effective way to treat the symptoms of sex hormone deficiency and with an individual approach to the appointment of therapy, the risk of complications is minimal. The effectiveness of alternative methods for correcting the symptoms of menopausal syndrome (MS) was been confirmed. Conclusion: MHT is indicated for all patients with MS, but there is low awareness of the effectiveness and high safety profile of such treatment. Alternative therapy for MS is the main choice for patients with a high risk of complications or if the patient refuses to use MHT.
Keywords: 
gynecology
menopause
climacteric syndrome
menopausal hormone therapy

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Women and health: today’s evidence tomorrow’s agenda. WHO report on the global situation. Geneva: World Health Organization, 2009. URL: https://www.who.int/gender/women_health_report/ru/
  2. World health statistics 2019: monitoring health for the SDGs, sustainable development goals. World Health Organization, 2019. URL: https://apps.who.int/iris/handle/10665/324835
  3. Federal'naja sluzhba gosudarstvennoj statistiki, 2019. Zdravoohranenie v Rossii. 2019: Statisticheskij sbornik. M.: Rosstat, 2019; 170 s. [Federal’naya sluzhba gosudarstvennoi statistiki, 2019. Zdravookhranenie v Rossii. 2019: Statisticheskii sbornik. M.: Rosstat, 2019; 170 s. (in Russ.)].
  4. Radzinskij V.E., Dobretsova T.A., Ryzhova T.E. Institut blagorodnyh... babushek. Biologicheskaja rol' menopauzal'nogo perehoda i terapevticheskie vozmozhnosti fitoestrogenov. StatusPraesens. Ginekologija. Akusherstvo. Besplodnyj brak. 2015; 4 (27): 77–82 [Radzinskii V.E., Dobretsova T.A., Ryzhova T.E. Institut blagorodnykh... babushek. Biologicheskaya rol’ menopauzal’nogo perekhoda i terapevticheskie vozmozhnosti fitoestrogenov. StatusPraesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2015; 4 (27): 77–82 (in Russ.)].
  5. Dreval' A.V. Menopauza (lektsija). RMZh. 2018; 1 (I): 3–7 [Dreval A.V. Menopause (lecture). RMJ. 2018; 1 (I): 3–7 (in Russ.)].
  6. Soules M.R., Sherman S., Parrott E. et al. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med. 2001; 10: 843–8. DOI: 10.1089/152460901753285732
  7. Demidova T.Ju., Zenina S.G., Gasanzade P.A. Novosti menopauzal'noj gormonal'noj terapii. Consilium Medicum. 2018; 20 (4): 47–51 [Demidova T.Yu., Zenina S.G., Gasanzade P.A. News on menopausal hormone therapy. Consilium Medicum. 2018; 20 (4): 47–51 (in Russ.)]. DOI: 10.26442/2075-1753_2018.4.47-51
  8. Siobán D., Margery G., Janet E. at al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19 (4): 387–95. DOI: 10.1097/gme.0b013e31824d8f40
  9. Gracia C.R., Sammel M.D., Freeman E.W. et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause. 2005; 12 (2): 128–35. DOI: 10.1097/00042192-200512020-00005
  10. Sowers M.R. et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008; 93: 3478–83. DOI: 10.1210/jc.2008-0567
  11. Rooij I.A., Broekmans F.J., Scheffer G.J. et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005; 83 (4): 979–87. DOI: 10.1016/j.fertnstert.2004.11.029
  12. Stuenkel C.A., Davis S.R., Gompel A. et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100 (11): 3975–4011. DOI: 10.1210/jc.2015-2236
  13. Prilepskaja V.N. Genitourinarnyj menopauzal'nyj sindrom: vozmozhnosti estriola. Ginekologija. 2018; 20 (1): 5–8 [Prilepskaya V.N. Genitourinary menopausal syndrome: the potential of estriol. Gynecology. 2018; 20 (1): 5–8 (in Russ.)]. DOI: 10.26442/2079-5696_20.1.5-8
  14. Gavisova A.A., Tverdikova M.A., Balushkina A.A. Klimaktericheskij sindrom: osobennosti terapii psihoemotsional'nyh narushenij. RMZh. 2009; 17 (20): 1408–11 [Gavisova A.A., Tverdikova M.A., Balushkina A.A. Klimaktericheskii sindrom: osobennosti terapii psikhoemotsional’nykh narushenii. RMJ. 2009; 17 (20): 1408–11 (in Russ.)].
  15. Low D.A., Hubing K.A., Del Coso J. et al. Mechanisms of cutaneous vasodilation during the postmenopausal hot flash. Menopause. 2011; 18 (4): 359–65. DOI: 10.1097/gme.0b013e3181f7a17a
  16. Tatarchuk T.F., Efimenko O.A. Printsipi dіagnostiki, profіlaktiki ta lіkuvannja klіmakterichnih rozladіv. Zhurnal ukraїns'koї lіkars'koї elіti. 2009; 4 (10): 24–9 [Tatarchuk T.F., Efimenko O.A. Principi dіagnostiki, profіlaktiki ta lіkuvannya klіmakterichnih rozladіv. Zhurnal ukraїns’koї lіkars’koї elіti. 2009; 4 (10): 24–9 (in Ukrain)].
  17. Klinicheskie rekomendatsii [Tekst]: Menopauzal'naja gormonoterapija i sohranenie zdorov'ja zhenschin v zrelom vozraste. Red. Suhih G.T., Smetnik V.P., Andreeva E.N. i dr. M., 2015 [Klinicheskie rekomendacii [Tekst]: Menopauzal’naya gormonoterapiya i sohranenie zdorov’ya zhenshchin v zrelom vozraste. Suhih G.T., Smetnik V.P., Andreeva E.N. et al. editors. M., 2015 (in Russ.)].
  18. Lucas R.A., Ganio M.S., Pearson J. et al. Brain blood flow and cardiovascular responses to hot flashes in postmenopausal women. Menopause. 2013; 20 (3): 299–304. DOI: 10.1097/gme.0b013e31826e45f0
  19. Hamoshina M.B., Rogovskaja S.I., Naumchik G.A. Aktual'nye vozmozhnosti farmakologii v profilaktike vozrastnyh narushenij. StatusPraesens. 2014; 1 (18): 75–81 [Khamoshina M.B., Rogovskaya S.I., Naumchik G.A. Aktual’nye vozmozhnosti farmakologii v profilaktike vozrastnykh narushenii. StatusPraesens. 2014; 1 (18): 75–81 (in Russ.)].
  20. Portman D.J., Gass M.L. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Woman’s Sexual Health and the North American Menopause Society. Maturitas. 2014; 79 (3): 349–54. DOI: 10.1016/j.maturitas.2014.07.013
  21. Dvorjanskij S.A., Emel'janova D.I., Jagovkina N.V. Klimaktericheskij sindrom: sovremennoe sostojanie voprosa. Vjatskij meditsinskij vestnik. 2017; 1 (53): 7–15 [Dvoryanskiy S.A., Emelyanova D.I., Yagovkina N.V. Climacteric syndrome: current status of the issue (literature review). Vyatskii meditsinskii vestnik. 2017; 1 (53): 7–15 (in Russ.)].
  22. Shestakova I.G., Simonovskaja H.Ju. Mikronizirovannyj estriol dlja mestnogo primenenija: katalizator kachestva zhizni v postmenopauze. StatusPraesens. Ginekologija. Akusherstvo. Besplodnyj brak. 2015; 2 (25): 78–84 [Shestakova I.G., Simonovskaya Kh.Yu. Mikronizirovannyi estriol dlya mestnogo primeneniya: katalizator kachestva zhizni v postmenopauze. StatusPraesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2015; 2 (25): 78–84 (in Russ.)].
  23. Shalina M.A., Jarmolinskaja M.I., Abashova E.I. Vlijanie gormonal'noj terapii na kostnuju tkan': mify i real'nost'. Zhurnal akusherstva i zhenskih boleznej. 2018; 67 (3): 83–94 [Shalina M.A., Yarmolinskaya M.I., Abashova E.I. The influence of hormonal therapy on bone tissue: myths and reality. Journal of Obstetrics and Women’s Diseases. 2018; 67 (3): 83–94 (in Russ.)]. DOI: 10.17816/JOWD67383-94
  24. Klinicheskie rekomendatsii [Tekst]: Menopauza i klimaktericheskoe sostojanie u zhenschiny. Red. Suhih G.T., Smetnik V.P., Jureneva S.V. i dr. M., 2016. [Klinicheskie rekomendacii [Tekst]: Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. Suhih G.T., Smetnik V.P., YUreneva S.V. et al. editors. M., 2016 (in Russ.)].
  25. Goodman N.F., Cobin R.H., Ginzburg S.B. et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. Endocr Pract. 2011; 17 (Suppl. 6): 1–25. DOI: 10.4158/ep.17.s6.1
  26. Jureneva S.V., Il'ina L.M., Jakushevskaja O.V. Menopauzal'naja gormonal'naja terapija v postmenopauze: kachestvo zhizni segodnja i v dolgosrochnoj perspektive. Ginekologija. 2016; 18 (1): 24–9 [Yureneva S.V., Ilyina L.M., Yakushevskaya O.V. Menopausal hormone therapy in postmenopausal women: the quality of life today and in the long term. Gynecology. 2016; 18 (1): 24–9 (in Russ.)].
  27. Kostroma Ja.V., Beljaeva E.N., Hazova E.L. i dr. Otsenka vyrazhennosti klimaktericheskogo sindroma i osobennosti psihosomaticheskogo statusa. Zhurnal akusherstva i zhenskih boleznej. 2019; 68 (1): 13–20 [Kostroma Ya.V., Belyaeva E.N., Khazova E.L., et al. Assessment of the severity of menopausal syndrome and psychosomatic peculiarities. Journal of Obstetrics and Women’s Diseases. 2019; 68 (1): 13–20 (in Russ.)]. DOI: 10.17816/JOWD68113-20
  28. Radzinskij V.E., Kostromina A.A. Sravnenie effektivnosti gormonal'nyh i negormonal'nyh metodov lechenija rannih projavlenij klimaktericheskogo sindroma. Mat' i ditja v Kuzbasse. 2017; 2 (69): 13–7 [Radzinskiy V.E., Kostromina A.A. Comparison of the effectiveness of hormonal and non;hormonal methods of treatment of early manifestations of climacteric syndrome. Mat’ i ditya v Kuzbasse. 2017; 2 (69): 13–7 (in Russ.)].
  29. Writing Group for the Women’s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002; 288 (3): 321–33. DOI: 10.1001/jama.288.3.321
  30. de Villiers T.J., Gass M.L.S., Haines C.J. et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric. 2013; 16 (2): 203–4. DOI: 10.3109/13697137.2013.771520
  31. North American Menopause Society. The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65. Menopause. 2015; 22 (7): 693. DOI: 10.1097/GME.0000000000000492
  32. Krasnopol'skij V.I., Zajdieva Ja.Z. Farmakologicheskie i klinicheskie aspekty menopauzal'noj gormonoterapii. M., 2016 [Krasnopol’skii V.I., Zaidieva Ya.Z. Farmakologicheskie i klinicheskie aspekty menopauzal’noi gormonoterapii. M., 2016 (in Russ.)].
  33. The North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012; 19 (3): 257–71. DOI: 10.1097/gme.0b013e31824b970a
  34. Tjuzikov I.A., Zhilenko M.I., Polikarpova S.R. Sovremennye vozmozhnosti optimizatsii lokal'noj gormonoterapii urogenital'nyh narushenij u zhenschin na osnove kombinirovannogo primenenija vaginal'nyh form estriola i progesterona. Ginekologija. 2018; 20 (1): 117–25 [Tyuzikov I.A., Zhilenko M.I., Polikarpova S.R. Modern possibilities of optimization of local hormonotherapy of urogenital disorders in women on the basis of combined use of vaginal forms of estriol and progesterone. Gynecology. 2018; 20 (1): 117–25 (in Russ.)]. DOI: 10.26442/2079-5696_20.1.117-125
  35. Il'ina I.Ju., Dobrohotova Ju.E., Ibragimova D.M. Al'ternativnye metody lechenija klimaktericheskogo sindroma. RMZh. 2018; 26 (2–1): 8–12 [Ilyina I.Yu., Dobrokhotova Yu.E., Ibragimova D.M. Alternative methods of treatment of menopausal syndrome. RMJ. 2018; 26 (2–1): 8–12 (in Russ.)].
  36. Zajdieva Ja.Z. Al'ternativnaja terapija menopauzal'nyh rasstrojstv u zhenschin v klimakterii. RMZh. 2017; 12: 873–8 [Zaydieva Y.Z. Alternative therapy of menopausal disorders in women of climacterical age (literature review). RMJ. 2017; 12: 873–8 (in Russ.)].
  37. Pachman D.R., Jones J.M., Loprinzi C.L. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health. 2010; 2: 123–35. DOI: 10.2147/ijwh.s7721
  38. Unanjan A.L., Kuzenkova N.N., Sidorova I.S. i dr. Menopauzal'naja terapija: preimuschestva i riski primenenija. RMZh. 2017; 15: 1128–34 [Unanyan A.L., Kuzenkova N.N., Sidorova I.S. et al. Menopausal therapy: benefits and risks. RMJ. 2017; 15: 1128–34 (in Russ.)].
  39. Shams T., Firwana B., Habib F. et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014; 29 (1): 204–13. DOI: 10.1007/s11606-013-2535-9
  40. Lapochkina N.P., Matasheva A.V., Krupenina E.A. Selektivnye ingibitory obratnogo zahvata serotonina pri klimaktericheskom sindrome. Vestnik Ivanovskoj meditsinskoj akademii. 2015; 20 (4): 34–8 [Lapochkina N.P., Matasheva A.V., Krupenina E.A. Selective inhibitors of serotonin reverse capture in the correction of psycho-vegetative disorders in women with climacteric syndrome. Vestnik Ivanovskoi meditsinskoi akademii. 2015; 20 (4): 34–8 (in Russ.)].
  41. Skrebitskij V.G., Kasjan A.P., Povarov I.S. i dr. Nejropeptidnyj preparat Selank: biologicheskaja aktivnost' i fundamental'nye mehanizmy dejstvija. Nervnye bolezni. 2016; 4: 52–7 [Skrebitsky V.G., Kasyan A.P., Povarov I.S. Biological Activity and Basic Mechanisms of Action of Selang – a Neuropeptide Product. Nervnye bolezni. 2016; 4: 52–7 (in Russ.)].
  42. Verbenko V.A., Fedorov V.N. Vozmozhnosti primenenija novogo anksiolitika peptidnoj prirody «Selank» v terapii psihogennogo pereedanija. Tavricheskij zhurnal psihiatrii. 2016; 20 (3): 5–13 [Verbenko V.A., Fedorov V.N. Vozmozhnosti primeneniya novogo anksiolitika peptidnoi prirody «Selank» v terapii psikhogennogo pereedaniya. Tavricheskii zhurnal psikhiatrii. 2016; 20 (3): 5–13 (in Russ.)].
  43. Verbenko V.A., Shakina T.A. Osobennosti anksioliticheskogo i stressoprotektivnogo dejstvija peptidnogo preparata Selank pri terapii rasstrojstv adaptatsii i posttravmaticheskogo stressovogo rasstrojstva. Meditsinskij alfavit. 2017; 3 (32): 21–6 [Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide Taftcin – Selank in therapy of adjustment and posttraumatic stress disorders. Meditsinskii alfavit. 2017; 3 (32): 21–6 (in Russ.)].
  44. Tereschenko O.N., Kost N.V., Medvedev V.E. i dr. Kupirovanie trevozhnyh rasstrojstv v obschemeditsinskoj praktike peptidnym preparatom Selank. Arhiv' vnutrennej meditsiny. 2016; 6 (S1): 115–6 (Tereshchenko O.N., Kost N.V., Medvedev V.E. et al. Therapy of anxiety disorders in general practice by peptide preparation Selank. Arkhiv vnutrennei meditsiny. 2016; 6 (S1): 115–6 (in Russ.)].
  45. Starikov P., Fedorov V. Ispol'zovanie Selanka v lechenii vegetativnyh i psihoemotsional'nyh rasstrojstv pri klimaktericheskom sindrome u zhenschin. Vrach. 2019; 30 (12): 48–53 [Starikov P., Fedorov V. The use of Selank in the treatment of autonomic and psychoemotional disorders in women with climacteric syndrome. Vrach. 2019; 30 (12): 48–53 (in Russ.)]. DOI: 10.29296/25877305-2019-12-13
  46. Chebotnikova T. V., Andreeva E. N. Defitsit androgenov u zhenschin – novye vozmozhnosti tkaneselektivnyh moduljatorov. Trudnyj patsient. 2006; 4 (9): 5–8 [Chebotnikova T. V., Andreeva E. N. Defitsit androgenov u zhenshchin – novye vozmozhnosti tkaneselektivnykh modulyatorov. Trudnyi patsient. 2006; 4 (9): 5–8 (in Russ.)].
  47. Podzolkova N.M., Podzolkov A.V. Renessans Tibolona. Znachenie dokazatel'noj meditsiny v otsenke effektivnosti, bezopasnosti i priemlemosti zamestitel'noj gormonal'noj terapii. Problemy reproduktsii. 2009; 15 (6): 71–6 [Podzolkova N.M., Podzolkov A.V. Renaissance of Tibolone: evidence-based research of efficacy, safety and compliance of hormonal replacement therapy. Problemy reprodukcii. 2009; 15 (6): 71–6 (in Russ.)].